Benitec Biopharma
Benitec Biopharma

Financials • Benitec Biopharma

BNTC

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
06/2018
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
06/2019
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
06/2020
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
06/2021
0
-13
-12
L
L
20
L
-20
-
-13
-0
23
-14
0
0
-
-
06/2022
0
-17
-12
L
L
3
L
-4
-
-17
-0
0
-17
0
0
-
-
06/2023
0
-19
-12
L
L
0
L
-2
-
-18
-0
16
-18
0
0
-
-
06/2024
-0
-22
-12
21,000%
L
47
L
-51
-
-20
-0
68
-20
0
0
-
-
06/2025
0
-41
-12
0%
L
97
L
-98
-
-41
-0
70
-41
0
0
-
-

To see all financials—including updated, you must be Premium.